Vernal now offers catalog hEPO mRNA that has been optimized to produce high expression level of human erythropoietin, a hormone that controls red blood cell production and maturation (erythropoiesis). Naturally produced in the kidneys in response to hypoxia, EPO also plays a role in wound healing and displays neuroprotective effects in response to brain injuries. hEPO mRNA is a common choice of mRNA to test therapeutic potential of different LNP designs for protein replacement therapy to treat diseases including anemia, neurological, and hepatic diseases.
Vernal’s mRNAs are highly pure mRNAs that incorporate modified nucleoside (N1-methylpseudoUridine), Cap-1 structure, optimized codons and poly(A) tail to improve translation efficiency and reduce host cell immune response. Vernal’s mRNAs function as mature, fully processed mRNAs, and are ready for use in cells and animals.